Overseas returnees with international technologies that address the pain points in medical antibacterial testing are seeking financing.
I. Core Pain Points in Multi-segment Medical Product Testing, Returned Overseas Talents Team Lands in Binjiang with Full Policy Support
Clinical data shows that more than 60% of chronic infections and device-related infections are induced by microbial biofilms, and the antimicrobial tolerance of microorganisms in biofilm state increases by 10–1000 times. At present, the R&D of indwelling implants such as vascular, urinary, oral, joint and cardiac devices, skin dressings, and antibacterial biomedicines in China generally faces common industry bottlenecks: traditional planktonic bacteria testing cannot replicate the real body fluids and body surface microenvironments of the human body, leading to a large number of products meeting the antibacterial standards in laboratory tests but failing in clinical applications, with a serious disconnect between experimental data and clinical results.
For a long time, accurate biofilm testing services that meet international standards have been monopolized by overseas institutions. The high testing costs and non-interoperable standards between China and foreign countries that lead to repeated testing have greatly raised the R&D and overseas expansion thresholds for domestic medical products. After identifying the industry gap, LI Yanqi, an overseas doctor who once worked at a leading international antibacterial testing enterprise, returned to China to start a business in cooperation with a Canadian expert with 12 years of industry experience, and registered Miru (Hangzhou) Inspection and Testing Co., Ltd. in the Biomedical Industrial Park of Hangzhou High-tech Zone (Binjiang) in March 2026, to build a domestic integrated testing platform for antibacterial, anti-adhesion and anti-biofilm functions that aligns with international standards.
Relying on the core team's high-end overseas work experience and complete reserves of international testing technologies, the project has been successfully selected into the "5050 Program" for overseas high-level leading talents in Binjiang, Hangzhou. Combined with the special policies for the biomedical industry in Binjiang, it enjoys a full-chain government support package covering the entire cycle of startup, R&D, site, financing, and talent credit: including special startup grants, step-by-step R&D subsidies, equity financing rewards, rent subsidies for office spaces in the industrial park, bank loan interest discounts for enterprises, and special subsidies for top talent cultivation. At the same time, the project can connect to the district-level 10-billion-yuan 5050 Special Talent Fund to obtain capital supporting services such as direct investment and follow-on investment, so as to comprehensively reduce the financial pressure on the construction of the startup technology platform.
Settling in the Binjiang Biomedical Industrial Park also allows Miru to be deeply embedded in the regional complete medical device and biomedical industrial cluster. The park is equipped with a flexible service station for medical innovation review under the Provincial Medical Products Administration, which can synchronously connect to resources for device registration, clinical transformation, and upstream and downstream enterprises, providing industrial ecological support for the commercial implementation of the platform. At present, the project has completed the basic hardware deployment of the laboratory relying on the 5050 policy startup funds and shareholders' own capital, with all core testing equipment in place, enabling stable implementation of routine antibacterial and biofilm-related experiments. At this stage, the team is openly seeking external financing in the market, which will be used to expand the market department to access more potential customer resources, supplement experimental equipment dedicated to segmented scenarios, build a LIMS laboratory digital management system, complete the validation of full-category testing methodologies, and simultaneously expand customers and industrial partners among enterprises engaged in implantable devices, dressings, and biomedical R&D.
II. Replicating Mature International Testing Systems, Customized Solutions for Multiple Scenarios to Solve the Disconnection Problem of Clinical Data
The core team of Miru has fully mastered the core testing technologies and full-process operation system of Canada's Innovotech Inc., eliminating the lengthy independent technology R&D cycle and directly realizing the localized implementation of cutting-edge international biofilm testing technologies, with the entire experimental system being mature and stable. Different from the homogeneous planktonic bacteria testing of domestic institutions, the platform has established a full-cycle evaluation system covering the formation, maturation, and inhibition of biofilms, and customized in-vivo real environment simulation testing solutions for diverse medical products, accurately solving the pain point of mismatch between laboratory and clinical data.
The platform's service categories cover the entire medical sector, not limited to traditional indwelling devices: the implantable device segment includes vascular interventional consumables, urinary catheters, oral implants, artificial joints, and cardiac implantable devices; medical body surface materials include various wound dressings and skin antibacterial dressings; at the same time, the platform provides biomedical enterprises with testing services for antibacterial agents and research on the anti-biofilm mechanism of new drugs. For different cavity fluids such as blood vessels, joints, oral cavities, and urinary tracts, as well as differentiated environments such as skin sweat and tissue exudate, exclusive simulation systems have been built respectively to highly restore the real usage scenarios of products. For long-term implantable devices such as cardiac and orthopedic devices, ultra-long-cycle antibacterial performance monitoring of 1–12 months or longer can be carried out; for dressings and skin external materials, the body surface environment is replicated to evaluate the long-term antibacterial effect; for pharmaceutical enterprises, the platform supports the iteration of new drug formulations and research on their action mechanisms, outputting effective experimental data that fits clinical practices.
The testing standards are bidirectionally compatible with domestic and international access requirements, and the entire process is aligned with mainstream international standards such as ISO, ASTM, USP and domestic NMPA registration regulations, helping enterprises reduce the cost of international registration testing by more than 50%. The standardized testing process improves turnover efficiency on the premise of ensuring high accuracy, which can shorten the new product R&D cycle of medical enterprises by more than 30%. The superposition of multiple technical barriers, together with Binjiang's sound policies and industrial resources, has made Miru a scarce high-end public testing platform in the domestic segmented field.
III. Expanding Market Demand, Building a Domestic Biofilm Testing Benchmark in Phases Relying on Policy Dividends
The market scale of domestic high-end implantable devices, oral consumables, cardiovascular equipment, wound dressings, and antibacterial new drug segments continues to expand, and the antibacterial and anti-biofilm performance has become the core differentiated competitiveness of products, leading to an explosive growth in industry demand for compliant, accurate, and clinical scenario-oriented testing. Relying on the full policy support of Binjiang's 5050 Program and the advantages of biomedical industry agglomeration, Miru has three-fold advantages in cost, technology, and channels, with industrial value covering multiple dimensions of enterprises, the industry, and public health.
For the enterprise side, the platform uses government subsidies to reduce its own operating costs, which can significantly cut the overseas testing expenses of local enterprises, eradicate the R&D difficulty of disconnection between experimental and clinical data, and accelerate the global registration and listing of domestic products. At the industry level, it breaks the technological and standard monopoly of overseas testing institutions, and drives the domestic antibacterial biofilm testing system to align with international standards. From a long-term perspective, accurate performance evaluation will force the improvement of the antibacterial performance of medical products, reduce the risk of device-, dressing- and drug-related clinical infections from the source, and consolidate the technical foundation of domestic public health safety.
Combined with policy support and industrial development pace, Miru has formulated a clear three-stage development path. In the short term, relying on the 5050 R&D subsidies and site subsidies, the company will complete the construction of a standardized laboratory quality management system and LIMS digital system, finish the verification of full-category testing methods for blood vessels, oral cavities, joints, skin dressings, and biomedical pharmaceuticals, gradually accept small-batch commercial orders, and accumulate service cases of leading enterprises in multiple sectors. In the next 2 to 5 years, the company will make full use of financing rewards and talent cultivation subsidies to expand its technical team, build an independent and complete testing methodology system, become a benchmark institution for antibacterial and biofilm testing in China, serve more than 100 medical device and biomedical enterprises in total, and support a number of domestic products to complete registration and certification at home and abroad. In the long run, the company will leverage Binjiang's talent fund and industrial capital resources to build a third-party professional testing platform with global competitiveness, drive the overall technological upgrading of the domestic antibacterial testing industry, and empower the global layout of domestic medical products.
LI Yanqi, the project leader, said that the core original intention of returning to China to start a business is to realize the localized implementation of mature international biofilm testing technologies. Relying on the sound 5050 talent support policy and biomedical industry ecosystem in Binjiang, Hangzhou, the team is directly addressing the core pain points of R&D and overseas expansion for medical enterprises across the industry. The team will continue to connect with the capital market and upstream and downstream industrial resources, make full use of multiple policy dividends such as startup grants, R&D subsidies, rent subsidies, loan interest discounts, and talent cultivation, fill the domestic gap in the high-end biofilm testing segmented field, and work together with industry peers to promote the high-quality and globalized upgrading of the domestic medical device and biomedical industries.